Product Information
ERYPED 400 MG/5 ML SUSPENSION is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $6.3072 per ML under NDC 24338013013. Its NADAC has been published 394 times since Nov 28, 2013.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/5mL
Manufacturer
Azurity Pharmaceuticals Inc.NDC
24338013013
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
1/22/2025
Active Ingredients
ERYTHROMYCIN ETHYLSUCCINATEApproval Type
New Drug (NDA)
FDA Application
NDA050207FDA Approved
Before 1982
TE Code
AB
On Market Since
6/14/2012
Pharmacological Classes
Price Statistics
The NADAC for ERYPED 400 MG/5 ML SUSPENSION has been published 394 times since Nov 28, 2013, and over the history we have for it it has risen 258.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.3072 per ML |
|---|---|
| All-time high | $6.3994 (Jan 11, 2017) |
| All-time low | $1.7582 (Nov 28, 2013) |
| 52-week high | $6.3072 |
| 52-week low | $6.3072 |
| Median price | $6.3072 |
| Average price | $5.6239 |
| Largest weekly change | +44.0% (Feb 11, 2015) |
| Weeks tracked | 394 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
0.0%
3Y
-0.6%
5Y
-0.6%
All
+258.7%
Last surveyed Jan 14, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 73% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ERYPED 400 MG/5 ML SUSPENSION?
The current National Average Drug Acquisition Cost (NADAC) for ERYPED 400 MG/5 ML SUSPENSION, manufactured by Azurity Pharmaceuticals Inc., is $6.3072 per ML (NDC 24338013013), effective Jan 14, 2026.
How has the price of ERYPED 400 MG/5 ML SUSPENSION changed over time?
Over the history we have for it, the NADAC for ERYPED 400 MG/5 ML SUSPENSION has risen 258.7%. It has been tracked across 394 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ERYPED 400 MG/5 ML SUSPENSION?
Since Nov 28, 2013, the NADAC for ERYPED 400 MG/5 ML SUSPENSION has ranged from a low of $1.7582 (Nov 28, 2013) to a high of $6.3994 (Jan 11, 2017), with a median of $6.3072 per ML.
Are there cheaper alternatives to ERYPED 400 MG/5 ML SUSPENSION?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ERYTHROMYCIN 400 MG/5 ML SUSP, is $1.7254 per ML — about 73% below ERYPED 400 MG/5 ML SUSPENSION.
Who manufactures ERYPED 400 MG/5 ML SUSPENSION?
ERYPED 400 MG/5 ML SUSPENSION (NDC 24338013013) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.